The study included over 200,000 patients who had undergone PCI and were prescribed low-dose aspirin. The researchers found that discontinuing aspirin one month after PCI did not increase the risk of major adverse cardiovascular events, such as myocardial infarction or stroke, compared to continuing aspirin therapy.
Subheading
The study was designed to evaluate the safety and efficacy of discontinuing aspirin therapy after PCI. Patients were randomly assigned to either continue aspirin therapy or discontinue it one month after the procedure. The primary outcome was the occurrence of major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular death.
The results showed that the risk of major adverse cardiovascular events was not significantly different between the two groups. This suggests that discontinuing aspirin one month after PCI may be a safe and effective strategy for some patients.
The findings have important implications for the management of patients after PCI, as they may help to reduce the duration of aspirin therapy and potentially reduce the risk of bleeding and other side effects associated with long-term aspirin use.